AXSM — Q2 2026 Financial Report Analysis

Overview

Axsome's second quarter of 2026 (three months to June 30) showed two things moving in opposite directions. Sales rose fast: total revenue was $218.4 million, up 45.5% from $150.0 million a year earlier, led by its depression drug Auvelity. But spending rose faster. Selling, general and administrative costs (SG&A, which covers the sales force, advertising and head office) climbed 59.8% to $208.1 million as the company paid for a national advertising campaign aimed directly at patients, a bigger sales force and the June launch of Auvelity for a second use: agitation in people with Alzheimer's dementia. The result was a net loss of $51.3 million ($0.99 per share), slightly wider than the $48.0 million ($0.97) loss a year ago.

At a glance

• Auvelity net sales: $180.3 million, up 50.8%. The drug now makes up 83% of product sales, so Axsome's story is mostly an Auvelity story.
• Operating margin: -22.7%, vs -24.5% a year ago. The operating loss (before interest and tax) grew in dollars, but shrank slightly as a share of revenue. Most of that apparent improvement disappears once a smaller accounting gain is stripped out (see below).
• Cash used by operations: $53.7 million in the first half, down from $75.8 million. Cash on hand stayed roughly flat at $319.9 million only because employees exercising stock options and share sales brought in about $71 million.

Results

Source: Axsome 10-Q for the quarter ended June 30, 2026. "n/m" = not meaningful.

What drove sales

The 10-Q attributes the product-sales increase "primarily" to higher unit volumes of Auvelity and Sunosi, meaning more prescriptions filled rather than price increases. By product:

• Auvelity (dextromethorphan-bupropion, approved for major depression in 2022): $180.3 million, up from $152.7 million in the first quarter of 2026, an 18% rise in one quarter. The FDA approved it in April 2026 for agitation associated with Alzheimer's dementia and Axsome began that launch in June, so at most one month of the new use is in these numbers. Most of the growth still came from depression.
• Sunosi (solriamfetol, for excessive daytime sleepiness in narcolepsy and sleep apnea): $33.8 million, up 17.0% year on year but only about 3% on the first quarter ($32.7 million). It is a steady, slower-growing product.
• Symbravo (a migraine pill launched June 2025): $2.3 million, down from $4.0 million in the first quarter. A year after launch, it is still a negligible contributor and its sales fell between quarters.
• Royalties and milestones added $2.0 million, mostly royalties from Pharmanovia's sales of Sunosi in Europe plus a $0.5 million Sunosi development milestone.

Cost of revenue (making and shipping the drugs, excluding amortization) was just $13.6 million, or 6.2% of revenue, down from 9.0% a year ago. Like most branded drugs, each extra sale costs very little to make, so profitability depends almost entirely on how much Axsome spends on selling and research.

Where the money went

SG&A was the whole story on the cost side. The company split it out in its segment note:

Management's explanation: "pre-launch activities for AUVELITY for the treatment of AADDAD [agitation in Alzheimer's dementia], higher commercial activities for AUVELITY including a national direct-to-consumer advertising campaign and sales force expansion, commercial activities for SYMBRAVO... and higher personnel costs." In plain terms: Axsome added $68.3 million of revenue year on year and spent $77.9 million more on SG&A to get it and to prepare the next launch.

Research and development fell 6.7% to $46.2 million, mainly because spending on AXS-05 trials and on AXS-14 (fibromyalgia) was lower this quarter due to timing, partly offset by more spending on solriamfetol trials. Over the half-year, R&D rose 4.9% to $98.9 million, mostly because of the $10.4 million paid to Takeda in the first quarter for the rights to AXS-20, a schizophrenia candidate.

What the headline numbers hide

• The year-ago comparison is distorted by one-offs on both sides. Q2 2025 included an $8.1 million gain from revaluing what Axsome owes Jazz in future Sunosi royalties (a "contingent consideration" liability), a $10.4 million loss from refinancing its debt, and a $1.0 million tax benefit. This quarter the revaluation gain was only $1.5 million. Strip out the revaluation gains and the operating loss was $51.1 million vs $44.8 million a year ago, so the underlying loss widened by about $6 million rather than improving. The slightly better operating margin is mostly that accounting gain, not operations.
• Stock-based pay is large. $27.1 million of this quarter's costs were stock-based compensation, a non-cash expense that dilutes shareholders instead. Excluding it, the net loss would have been about $24 million. The weighted share count rose 4.8% in a year, to 51.8 million, which is why the loss per share barely moved even though the dollar loss grew 7%.
• Cash conversion is better than the loss, but helped by timing. First-half operating cash outflow was $53.7 million against a $115.9 million net loss. The gap is mostly stock-based pay ($50.6 million) and a $63.8 million rise in accrued expenses. Much of that accrual is rebates owed but not yet paid: reserves for discounts, rebates and returns rose from $172.5 million to $233.2 million in six months, and the Medicare/Medicaid rebate reserve alone went from $45.2 million to $77.4 million. That cash will go out later.
• Receivables are growing fast. Money owed by wholesalers rose $53.0 million in the half to $277.5 million, about 1.3 times this quarter's revenue. Inventory rose 36% to $37.9 million, consistent with stocking up for the Alzheimer's-agitation launch.
• Discounts are heavy. In the first half, Axsome booked $420.2 million of discounts, rebates and returns against $405.8 million of net product sales. In rough terms, roughly half of the list-price value of sales goes back to insurers, government programs and wholesalers. This matters because the Alzheimer's population is largely on Medicare, where rebates are high, so the price Axsome actually keeps on new Auvelity prescriptions may trend lower.
• Debt and funding. Axsome has $188 million of borrowings ($70.0 million short-term, $118.0 million long-term) under its Blackstone loan, against $319.9 million of cash. It also sold $19.5 million of new shares through its at-the-market program in the first half.

Takeaway: Auvelity's 51% growth is real and comes from more prescriptions, but Axsome is still spending more than every extra dollar of revenue on marketing and launch costs, so the underlying loss widened this quarter. The case for the stock rests on whether the June launch in Alzheimer's agitation lifts Auvelity sales faster than SG&A from here, which management says will grow only "marginally" for the rest of 2026.

Outlook

Management did not give revenue or earnings guidance in the 10-Q, but it did say three things about the rest of 2026:

• SG&A is expected to "marginally increase through the end of 2026." With most launch costs already in the run rate, revenue growth should start to outpace selling costs if that holds.
• R&D is expected to "moderately increase" as recently started trials enroll more patients.
• Management believes current cash is "sufficient to fund anticipated operations into cash flow positivity" on its current plan, i.e. no further fundraising is planned to reach the point where operations pay for themselves. No date was given.

Pipeline dates to watch:

• AXS-12 (reboxetine) for cataplexy in narcolepsy: FDA accepted the application in July 2026, with a decision date of May 1, 2027.
• AXS-14 for fibromyalgia: the FDA previously refused to review the application; Axsome plans to resubmit and began a new Phase 3 trial (FORWARD) in January 2026.
• Solriamfetol: Phase 3 trials are under way in ADHD in children and adolescents, depression with daytime sleepiness, binge eating disorder and shift-work sleepiness. A successful ADHD result would widen Sunosi's market well beyond sleep disorders.

Our read: the second half of 2026 is the test. The Alzheimer's-agitation label only contributed for a few weeks of Q2, and Auvelity was already growing 18% quarter on quarter before it. If Q3 shows Auvelity growing at a similar or faster pace while SG&A stays near $210 million, the operating loss should narrow meaningfully. If SG&A keeps rising in step with sales, or Medicare rebates compress what Axsome keeps per prescription, break-even moves further out. Symbravo's falling sales are a smaller worry, but worth watching as evidence of how hard it is to grow a new migraine brand.